NBER WORKING PAPER SERIES

PUBLIC INSURANCE AND PSYCHOTROPIC PRESCRIPTION MEDICATIONS
FOR MENTAL ILLNESS
Johanna Catherine Maclean
Benjamin L. Cook
Nicholas Carson
Michael F. Pesko
Working Paper 23760
http://www.nber.org/papers/w23760

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
August 2017, Revised March 2018

Johanna Catherine Maclean, Benjamin Le Cook, and Michael Pesko were supported by a
Research Scholar Grant â€“ Insurance, RSGI-16-019-01 â€“ CPHPS, from the American Cancer
Society. We thank Joachim Marti, Douglas Webber, and session participants at the 2017
International Health Economics Association World Congress for helpful comments. The views
expressed herein are those of the authors and do not necessarily reflect the views of the National
Bureau of Economic Research.
NBER working papers are circulated for discussion and comment purposes. They have not been
peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies
official NBER publications.
Â© 2017 by Johanna Catherine Maclean, Benjamin L. Cook, Nicholas Carson, and Michael F.
Pesko. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted
without explicit permission provided that full credit, including Â© notice, is given to the source.

Public Insurance and Psychotropic Prescription Medications for Mental Illness
Johanna Catherine Maclean, Benjamin L. Cook, Nicholas Carson, and Michael F. Pesko
NBER Working Paper No. 23760
August 2017, Revised March 2018
JEL No. I1,I13,I18
ABSTRACT
Mental illnesses are prevalent in the United States and globally. Cost is a critical barrier to
treatment receipt. We study the effects of recent and major eligibility expansions within
Medicaid, a public insurance system for the poor in the U.S., on psychotropic prescription
medications for mental illness. We estimate differences-in-differences models using
administrative data on medications for which Medicaid was a third-party payer over the period
2011 to 2017. Our findings suggest that these expansions increased psychotropic prescriptions by
22.3%. We show that Medicaid, and not patients, financed these prescriptions. For states
expanding Medicaid, the total cost of these prescriptions was $30.8M. Expansion effects were
experienced across most major mental illness categories and across states with different levels of
patient need, system capacity, and expansion scope. We find no evidence that Medicaid
expansion reduced a proxy for serious mental illness: suicide.
Johanna Catherine Maclean
Department of Economics
Temple University
Ritter Annex 869
Philadelphia, PA 19122
and NBER
catherine.maclean@temple.edu
Benjamin L. Cook
Cambridge Health Alliance
1035 Cambridge Street
Cambridge, MA 02141
bcook@charesearch.org

Nicholas Carson
Cambridge Health Alliance
1035 Cambridge Street
Cambridge, MA 02141
ncarson@charesearch.org
Michael F. Pesko
Department of Economics
Andrew Young School of Policy Studies
Georgia State University
PO Box 3992
Atlanta, GA 30302-3992
mpesko@gsu.edu

1. Introduction
Mental illnesses are prevalent in the United States and other developed countries (World
Health Organization 2017). For example, in 2015 17.9% of U.S. adults met the diagnostic
criteria for any mental illness and 4% met criteria for a serious mental illness (Center for
Behavioral Health Statistics and Quality 2016). The American Psychiatric Association (APA),
the primary professional organization of psychiatrists in the U.S., defines mental illness as
â€˜health conditions involving changes in thinking, emotion or behavior (or a combination of
theseâ€™ (American Psychiatric Association 2015). Further, according to the APA, mental illnesses
are â€˜associated with distress and/or problems functioning in social, work or family activitiesâ€™.
Mental illnesses thus impose heavy burdens on afflicted individuals as these illnesses
harm overall health, employment, and relationships (World Health Organization 2017). In
addition to imposing costs internalized by afflicted individuals, mental illnesses levy costs on
broader society (Frank and McGuire 2000). Each year mental illnesses cost the U.S. economy
$504B in healthcare expenditures, disability payments, and a less productive work force (Insel
2015). 1 Mental illness prevalence is not homogenous across the population; less advantaged
groups are more likely to suffer from such illnesses (World Health Organization 2017). Within
the U.S., mental illness prevalence is particularly high among low income and uninsured
individuals (Center for Behavioral Health Statistics and Quality 2016).
Although they impose substantial costs, mental illnesses can be effectively treated. For
example, primary care providers prescribe psychotropic medications (medications used to treat
mental illnesses such as anxiety, depression, and psychosis) and provide brief counseling (Olfson
2016). Additionally, specialty providers (e.g., psychiatrists and psychologists) provide intensive

1

The authors inflated this number from the original estimate ($467B in 2012 dollars) to 2017 dollars using the
Consumer Price Index.

2

psychopharmacological and psychosocial treatment in outpatient or inpatient settings (Olfson
2016). Despite established treatment efficacy (American Psychiatric Association 2006), there is
a substantial amount of unmet need for mental illness treatment in the U.S. According to
National Survey on Drug Use and Health (NSDUH) data, in 2015, more than half of U.S. adults
who could benefit from mental illness treatment did not receive any treatment (Center for
Behavioral Health Statistics and Quality 2016). Unmet need for mental illness treatment is
particularly high for uninsured individuals (Garfield et al. 2011). Among those who sought care
but did not receive it, the most commonly reported reason for failure to receive care was inability
to pay for treatment (Center for Behavioral Health Statistics and Quality 2016). Thus, expanding
affordable insurance coverage to low-income, uninsured individuals may remove cost-related
barriers to unmet mental illness treatment needs and, in turn, reduce mental illness.
In 2010, the U.S. federal government implemented the Affordable Care Act (ACA). This
Act, arguably the most substantial U.S. healthcare legislation in a generation, was designed to
address perceived inadequacies within the healthcare delivery system. A primary objective of
the Act was to reduce the level of uninsurance. The ACA increased insurance coverage through
three levers: premium subsidies for private insurance, mandates that required employers to offer
insurance and individuals to hold insurance, and expanded eligibility for Medicaid; a public
insurance system that finances healthcare services for the poor (Frean, Gruber, and Sommers
2017). In 2009 the uninsurance rate was 15.4% (Cohen, Martinez, and Ward 2010); by 2017 the
rate had fallen to 9% (Zammitti, Cohen, and Martinez 2017). Another objective of the ACA was
to mitigate â€˜underinsuranceâ€™: insurance that provides inadequate coverage of healthcare services.
In particular, the ACA required that most insurance plans, including plans for individuals who
gained eligibility through Medicaid expansion, cover ten benefit classes, including mental illness

3

treatment and prescription medications (Garfield, Lave, and Donohue 2010). Historically,
insurance has covered mental health services less generously than general healthcare services.
We explore the effects of ACA-related Medicaid expansions that occurred between 2011
and 2017 on psychotropic medications prescribed in outpatient settings for which Medicaid was
a third-party payer. While we do not directly capture medication use, prescriptions arguably
provide a reasonable clinical proxy for such use (Lehmann et al. 2014) and are commonly used
as a proxy in economics (Richards et al. 2017; Bradford and Lastrapes 2013). Analyses of preACA data suggest that individuals who gained eligibility through these expansions had elevated
need for mental illness treatment (Garfield et al. 2011; Cook et al. 2016), which implies that
newly insured populations may benefit from these expansions.
Psychotropic medication treatment is endorsed by providers â€“ in professional practice
treatment guidelines these medications are recommended as a component of treatment for most
major mental illnesses (American Psychiatric Association 2017) â€“ and common â€“ in 2015,
36.7% of U.S. adults with mental illness used psychotropic medications (Center for Behavioral
Health Statistics and Quality 2016). Moreover, access to insurance that covers these medications
likely leads to a substantial reduction in out-of-pocket price faced by uninsured individuals
seeking treatment; reimbursement rates for mental healthcare providers (e.g., psychologists)
range from $67 to $114 per visit (Mark et al. 2017) 2 and thus this modality of care is likely
unaffordable for many low-income and uninsured individuals.
We couple administrative data on the universe of prescriptions obtained in outpatient
non-specialty settings, and purchased through retail and online pharmacies for which Medicaid
was a third-party payer between 2011 and 2017 with differences-in-differences models to

2

This estimate is derived from commercial insurance claims and may depart from costs faced by an uninsured
patient with mental illness.

4

estimate Medicaid effects. Our findings suggest that, post-expansion, psychotropic prescriptions
increased 22.3% in expansion states relative to non-expansion states, and effects increased over
time in the post-expansion period. The costs of the new prescriptions to state Medicaid programs
were roughly $2.2M per quarter. Effects were relatively homogeneous across psychotropic class
and state characteristics that proxy for patient need, system capacity, and expansion scope.
The paper proceeds as follows. Section 2 offers a discussion of Medicaid, with emphasis
on the ACA expansions we study, and the related literature. Data, variables, and methods are
outlined in Section 3. Results are reported in Section 4. Extensions to the main analysis and
robustness checking are reported in Section 5. A discussion is provided in Section 6.
2. Medicaid and related literature
2.1 Medicaid and ACA-related expansions
Established in 1965, Medicaid is the primary insurer for low-income families, lowincome elderly Medicare beneficiaries, and disabled individuals in the U.S., covering 77 million
individuals in 2017 (Sommers and Grabowski 2017). Medicaid is a joint federal-state program.
States historically had ample latitude to determine specific eligibility criteria and benefit design
within federal standards. Prior to the ACA, most states limited Medicaid eligibility to the
disabled and low-income parents; other low-income groups were not eligible for coverage.
Medicaid is characterized by low patient cost-sharing and coverage of a relatively expansive list
of healthcare services, including mental illness services (Kaiser Family Foundation 2017). Of
particular relevance to our study, comparison of plans suggests that Medicaid may provide more
generous coverage for mental illness services than many private insurance plans (Garfield, Lave,
and Donohue 2010; Rosenbaum et al. 2015).

5

Beginning in 2014, as part of the ACA, Medicaid was expanded in 31 states and the
District of Columbia (as of March, 2018) to cover parents and other non-disabled adults with
incomes up to 138% of the Federal Poverty Level [FPL] (Kaiser Commission on Medicaid and
the Uninsured 2016). 3 Categorical restrictions were removed. Individuals who gained eligibility
through these Medicaid expansions are referred to as â€˜newly eligibleâ€™ and are insured by
â€˜expansionâ€™ plans that generously cover both mental illness treatment and prescription
medications (Garfield, Lave, and Donohue 2010). Originally, the ACA legislated that the
Medicaid expansion was to occur nationally. However, in 2012, the U.S. Supreme Court ruled
that states would have the discretion whether to expand Medicaid.
Economic theory suggests that Medicaid expansions, by reducing out-of-pocket prices,
will increase the quantity of prescriptions demanded by the newly enrolled suffering from mental
illnesses (Grossman 1972). Moreover, increased awareness of mental illness treatment and its
benefits may occur with Medicaid expansion either through public information campaigns or
through connection with general healthcare providers, which may increase demand for
psychotropic medications. There are numerous factors that may mute expansion effects. For
instance: mental illness and treatment stigma, new patientsâ€™ unfamiliarity with the healthcare
delivery system, limited participation in Medicaid by healthcare providers, well established
mental healthcare provider shortages, and so forth (Decker 2012; Center for Behavioral Health
Statistics and Quality 2016; Bishop et al. 2014; Thomas et al. 2009). Thus, the extent to which
Medicaid expansions lead to increases in psychotropic medication prescriptions is ultimately an
empirical question. We attempt to provide empirical evidence on this relationship.

3

Maine and Virginia have passed legislation to expand Medicaid. At the time of writing an effective date for these
expansions has not been determined.

6

Although we emphasize the newly eligible population in our study, other groups
experienced changes in insurance status and eligibility post-ACA. Through â€˜welcome matâ€™
effects, individuals who were previously eligible enrolled in Medicaid (Frean, Gruber, and
Sommers 2017). In all states income eligibility was increased by five percentage points on
January 1st 2014; this increase occurred with the federal governmentâ€™s transition to the â€˜Modified
Adjusted Gross Incomeâ€™ [MAGI] criteria for determining program eligibility 4 (â€˜MAGI effectsâ€™).
For expansion states the post-ACA income threshold is 138% of FPL (133% plus 5 percentage
points) and for non-expansion states the post-ACA income threshold is 5 percentage points
above the stateâ€™s Medicaid income threshold in March 2010. These groups are not referred to as
newly eligible and are not covered by expansion plans (Garfield, Lave, and Donohue 2010).
However, most states covered mental illness treatment in traditional Medicaid plans.
In our main analyses, we leverage variation in Medicaid eligibility for the newly eligible
group, but we note the possibility that welcome mat and MAGI effects may differ across
expansion and non-expansion states. In extensions, we explore and discuss the extent to which
our effects reflect increased prescriptions within the newly eligible population specifically.
A robust and growing literature shows that the ACA Medicaid expansions lead to large
decreases in the uninsured rate (Wherry and Miller 2016; Frean, Gruber, and Sommers 2017;
Sommers et al. 2015; Miller and Wherry 2017). Moreover, Medicaid expansions increased
access to care as measured by having a personal doctor, receiving an annual check-up, and
ability to pay for needed treatment (Sommers et al. 2016; Sommers et al. 2017; Miller and
Wherry 2017); improved financial security (Hu et al. 2016); and improved health (Simon, Soni,

4

More details are available at https://www.healthcare.gov/glossary/modified-adjusted-gross-income-magi/ [accessed
August 17th, 2017].

7

and Cawley 2017; Winkelman and Chang 2017; Koma et al. 2017). 5 These expansions did not
lead to substantial crowd-out of private insurance (Frean, Gruber, and Sommers 2017;
Courtemanche et al. 2017; Kaestner et al. 2017; Wherry and Miller 2016).
2.2 Medicaid and mental illness
There is relatively little evidence on the effect of Medicaid expansion on mental illness
treatment; especially compared with the volumes literature on general healthcare services. In
particular, little is known on the effects of Medicaid expansions on psychotropic medications.
Three studies examine the effects of Medicaid on overall mental illness service use and
unmet treatment need using variation afforded by pre-ACA state expansions and offer conflicting
findings. Golberstein and Gonzales (2015) find little effect of Medicaid on mental illness service
use using the Medical Expenditure Panel Survey. On the other hand, Wen, Druss, and
Cummings (2015) utilize NSDUH data to show Medicaid expansions increased the probability of
receiving mental illness treatment and reduced reports of unmet treatment need. Similarly,
Baicker et al. (2017) leverage a randomized control trial in the state of Oregon and show that
individuals randomized to Medicaid were more likely to use psychotropic medications than
individuals randomized to the control group.
While these studies are important, they have primarily focused on traditional Medicaid
populations and/or the pre-ACA period. Moreover, their findings are mixed. 6 In comparison,
we examine expansions to non-traditional populations â€“ low-income and non-disabled adults â€“ in
a very recent time period across U.S. states. Moreover, while two of the three above-noted

5

We note that not all studies demonstrate self-assessed health gains. See, for example, Courtemanche et al. (2017)
and Miller and Wherry (2017).
6
We suspect that differences in Medicaid expansion modelling may play a role. Golberstein and Gonzales impute
Medicaid eligibility following Cutler and Gruber (1996). Wen et al use indicator variables for a Section 1115
waivers. See Hamersma and Kim (2013) for a discussion of approaches to modelling pre-ACA Medicaid
expansions. Differences in covariates, time periods, and survey frame may also play a role. Finally, Baiker et al
rely on a lottery that occurred in a single state.

8

studies examine mental illness treatment overall, we examine psychotropic medications.
Psychotropic medications filled by physicians and other providers in outpatient and primary care
settings can allow individuals to fulfill standard work and family commitments and are likely
less stigmatized, therefore are perhaps more appealing to patients than other forms of treatment
(e.g., care received in specialty treatment facilities such as a residential rehabilitation center).
To the best of our knowledge, only one study examines the effect of ACA-related
Medicaid expansions on mental illness treatment. In an extension to their main analyses of
overall prescriptions, Ghosh, Simon, and Sommers (2017), using all payer claims data, find that
psychotropic medications increased 19%, post-expansion, in expanding states relative to nonexpanding states (overall prescriptions increased by the same percent). Our analysis builds on
the Ghosh, Simon, and Sommers (2017) analysis in at least seven important ways. (i) We assess
heterogeneity across major classes of psychotropic medications. (ii) We estimate the costs of
increases in psychotropic medication and changes in prescribing patterns. (iii) We test the extent
to which state Medicaid programs vs. patients assumed the financial responsibility of increased
psychotropic medication prescriptions. While Medicaid co-payments are federally regulated to
low levels (e.g., a maximum of $4 to $8 for enrollees up to 150% FPL), previous research shows
that such cost-sharing can reduce medication use within Medicaid (Soumerai et al. 1991;
Soumerai et al. 1987; Abdelgawad and Egbuonu-Davis 2006; Ridley and Axelsen 2006). 7 (iv)
We examine how Medicaid effects vary across state characteristics that proxy for patient need,
system capacity, and expansion scope. (v) We are able to study a much longer-term expansion
effects as we have access to 42 months post-expansion (vs. 15 post-expansion months examined

7

We note that a small number of states use Waivers that allow higher cost-sharing. On the other hand, several
groups (e.g., pregnant women) are exempt from cost-sharing.

9

by Ghosh and colleagues). (vi) We attempt to isolate effects for the newly eligible population.
(vii) We investigate the effects of Medicaid expansion on serious mental illness.
3. Data and methods
3.1 Prescription medications
We draw data on Medicaid-financed prescription medications from the State Drug
Utilization Database (SDUD). The Centers for Medicaid and Medicare (CMS) compile the
SDUD using state data supplied by Medicaid programs. The SDUD includes the universe of
outpatient prescription medications purchased at retail and online pharmacies and covered under
the Medicaid Drug Rebate Program for which Medicaid serves as a third-party payer (U.S.
Department of Health and Human Services 2012). The purpose of the SDUD is to allow the
Department of Health and Human Services to determine state and federal rebates from
approximately 600 pharmaceutical companies involved in the Medicaid Drug Rebate program.
While the SDUD has included information from fee-for-service since its inception, data
on prescriptions financed by managed care plans were added to the SDUD in March 2010 (U.S.
Department of Health and Human Services 2012). We use data from 2011 onward to examine
both fee-for-service and managed care given the movement toward managed care within
Medicaid over time (Hurley and Somers 2003). For example, in most expansion states over 80%
of newly eligible enrollees are enrolled in managed care plans and in some expansion states the
share is over 90% (Paradise 2017). 8
We use SDUD data in all quarters between Q1 2011 and Q2 2017, yielding 24 periods of
data for each state and DC: 12 periods pre-2014 and 14 periods post-2014. We exclude Kansas

8

In our main analysis, for states that have both types of plans we sum across fee-for-service and managed care plans
to construct our prescription count variable. If a state offers just one type of plan (fee-for-service or managed care)
we simply sum across that plan. More details are available on request.

10

and Rhode Island due to odd missing data patterns. We study overall prescriptions for
medications with indications for mental illnesses, and consider heterogeneity across major
psychotropic groups: anti-depressants, anti-anxiety medications, anti-psychotics, mood
stabilizers, and stimulants. 9 Medications are listed in Table 1.
To form the set of medications to examine, we first use medications provided by the
National Institute of Mental Health to identify the medications in each psychotropic class. Next
we refer to each medicationsâ€™ Medline webpage to broaden the list of included medications.
Only medications with Food and Drug Administration (FDA) indicators for treatment of adult
mental illness are included in our analyses. 10 We identify medications in the SDUD with
crosswalks between National Drug Codes (Roth 2017).
We note that this list does not provide a complete enumeration of all psychotropic
medications used to treat mental illness. We argue that the selected medications reflect a
substantial share of medications plausibly available to a Medicaid patient. Our medication
selection was further informed by one of the authors who is a practicing psychiatrist. Further, a
limitation of studying psychotropic medications specifically, and prescription medications
generally, is that some medications are used for treatment of other health conditions. For
example, Zyban, a medication used to treat depression, is also used to treat smoking cessation
(Maclean, Pesko, and Hill 2017).
3.2 Medicaid expansions

9
Anti-depressants are indicated for depression treatment (e.g., major depressive disorder), anti-anxiety medications
are indicated for anxiety treatment (e.g., generalized anxiety, obsessive compulsive disorder, panic disorder), antipsychotics are indicated for treatment of psychosis (e.g., schizophrenia), mood stabilizer medications are indicated
for treatment of mood disorders (e.g., bipolar disorder), and stimulants are indicated for treatment of attention-deficit
hyperactivity disorder (ADHD).
10
https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml (accessed May 5th, 2017).

11

Our classification of expansion states and expansion dates follows Maclean, Pesko, and
Hill (2017) and is listed in Table 2. The majority of states expanded Medicaid on January 1st,
2014. Two states expanded later in 2014 (Michigan, New Hampshire). Five states expanded in
2015 or 2016 (Alaska, Indiana, Louisiana, Montana, Pennsylvania). Prior to 2011, four states
(Delaware, Massachusetts, New York, Vermont) and the District of Columbia expanded
Medicaid eligibility to cover parents and childless adults with full benefits through 100% FPL or
higher, and continued to enroll new beneficiaries. We code these states as treated in all periods.
We match Medicaid expansion dates to the SDUD by state, year, and quarter. For within-quarter
expansions, we code the first quarter in which the expansion was in place.
3.3 Outcomes
We construct the number Medicaid-financed prescriptions for psychotropic medications
per 100,000 18-64 year olds in the state. We use data from the U.S. Census on population and
the Current Population Survey (CPS) on age (Flood et al. 2017). This population is the target of
ACA-related Medicaid expansions (Frean, Gruber, and Sommers 2017).
3.4 Empirical model
Our differences-in-differences (DD) model is specified in Equation (1):
(1)

ğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  = ğ›¼ğ›¼0 + ğ›¼ğ›¼1 ğ¸ğ¸ğ¸ğ¸ğ‘ ğ‘ ğ‘ ğ‘  + ğ›¼ğ›¼2â€² ğ‘‹ğ‘‹ğ‘ ğ‘ ğ‘ ğ‘  + ğ‘†ğ‘†ğ‘ ğ‘  + ğœğœğ‘¡ğ‘¡ + Î©ğ‘ ğ‘ ğ‘ ğ‘  + ğœ€ğœ€ğ‘ ğ‘ ğ‘ ğ‘ 

ğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  is the psychotropic prescription rate in state s in state and in year/quarter (â€˜periodâ€™) t.

ğ¸ğ¸ğ¸ğ¸ğ‘ ğ‘ ğ‘ ğ‘  is an indicator for whether or not a state has expanded its Medicaid program in period t.
ğ‘‹ğ‘‹ğ‘ ğ‘ ğ‘ ğ‘  is a vector of time-varying state characteristics from the CPS: unemployment rate among

non-elderly adults and demographics (age, sex, race, ethnicity, non-U.S. birth, and education).
ğ‘†ğ‘†ğ‘ ğ‘  and ğœğœğ‘¡ğ‘¡ are vectors of period fixed effects. State fixed effects control for time-invariant state

factors while period fixed effects control for national trends in prescriptions. We also include

12

state-specific linear time trends (Î©ğ‘ ğ‘ ğ‘ ğ‘  ). ğœ€ğœ€ğ‘ ğ‘ ğ‘ ğ‘  is the error term. We use unweighted OLS and report
95% confidence intervals that account for within-state clustering.
3.5 Internal validity testing
A necessary assumption for the DD model to recover causal estimates is that the
treatment and comparison groups would have followed the same trend in the post-treatment
period, had the treatment states not been treated. This assumption is untestable as expansion
states did expand Medicaid and thus we cannot observe these states in the untreated state postexpansion. We attempt to provide suggestive evidence on this assumption in two ways.
(i) We examine unadjusted trends in the pre-expansion period in our outcome variables
for the treatment group and 2011-2013 for the comparison group. If we find that the outcomes
appear to have trended similarly in the pre-treatment period across these groups, such trends
provide suggestive evidence that the SDUD data satisfy the parallel trends assumption. (ii)
Using pre-Medicaid expansion data for each expanding state and 2011-2013 data for nonexpanding states, 11 we estimate the OLS regression model outlined in Equation (2):
(2)

ğ‘€ğ‘€ğ‘ ğ‘ ğ‘ ğ‘  = ğ›¾ğ›¾0 + ğ›¾ğ›¾1ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘ ğ‘  âˆ— ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘¡ğ‘¡ + ğ›½ğ›½2â€² ğ‘‹ğ‘‹ğ‘ ğ‘ ğ‘ ğ‘  + ğ‘†ğ‘†ğ‘ ğ‘  + ğœğœğ‘¡ğ‘¡ + ğœ–ğœ–ğ‘ ğ‘ ğ‘ ğ‘ 

ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘ ğ‘  âˆ— ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘¡ğ‘¡ is an interaction between the treatment group indicator and a linear time

trend. 12 If we cannot reject the null hypothesis that ğ›¾ğ›¾1 is zero, this finding provides support that
our data satisfy the parallel trends assumption. States with substantial expansions prior to 2011
are excluded from validity tests (see Table 2).
4. Results
4.1 Summary statistics

11

We use 2011-2013 data for states that expanded Medicaid after January 1st, 2014 in validity testing (see Table 2).
We do not include state-specific linear time trends in Equation (2) because these would be perfectly collinear with
our main interaction testing for pre-expansion parallel trends between expanding and non-expanding states.
12

13

Table 3 reports summary statistics for expansion and non-expansion states in the period
2011-2013; states with substantial expansions before 2011 are excluded. In expansion states the
quarterly number of psychotropic prescriptions per 100,000 non-elderly adults was 9,731 and in
non-expansion states the number was 9,068. Turning to control variables, there were clear level
differences between expanding and non-expanding states in the pre-expansion period; e.g., lower
unemployment rates in expanding states. We control for these variables in all regressions.
4.2 Internal validity testing
Figure 1 reports graphical analysis of trends in outcomes aggregated to the quartertreatment level; we exclude states that expand prior to January 1st, 2014. Psychotropic
prescriptions in treatment and comparison states moved broadly in parallel pre-expansion. Postexpansion, psychotropic prescriptions increased in expanding states relative to non-expanding
states, and differences between the groups grew over time.
Table 4 reports regression-based parallel trends testing. We cannot reject the null
hypothesis that the treatment and comparison groups followed the same trend in psychotropic
prescriptions pre-expansion: ğ›¾ğ›¾ï¿½1 is not statistically different from zero and is small in magnitude
(-30 or -0.3% relative to the pre-ACA mean in expansion states). 95% confidence intervals are
relatively tight and allow us to rule out pre-expansion trend differences between expansion and
non-expansion states of -1.3% and +0.7% (relative to the pre-ACA expansion state mean).
4.3 Differences-in-differences regressions: Prescriptions
Table 5 reports the main DD results. Post-expansion, psychotropic prescriptions
increased by 2,174 per quarter per 100,000 non-elderly adults in expanding states relative to nonexpanding states, or a 22.3% increase relative to the baseline mean prescription rate in expanding
states in the pre-expansion period (9,731).

14

We next consider heterogeneity by psychotropic class. Relative to other insured
individuals, those covered by Medicaid suffer from high rates of mood disorders, anxiety
disorders, trauma-based disorders, psychotic disorders, and attention deficit/hyperactivity
disorder (ADHD) (Adelmann 2003). Of these illnesses, depressive and anxiety disorders are the
most prevalent among Medicaid enrollees, and the most likely to be treated in primary care
settings similar to settings that lead to prescriptions captured by the SDUD. Bipolar disorder and
psychotic disorders are more likely to be treated in specialty settings, given the higher severity of
both clinical symptoms and side effect profiles of mood stabilizers and antipsychotic
medications. Primary care providers feel less comfortable than specialty providers to prescribe
stimulant medications for the treatment of ADHD given the addictive potential of these
medications and the difficulty of accurate ADHD diagnosis in adults (Morrill 2009). The FDA
has approved psychotropic medications for all of these categories, and numerous studies confirm
their effectiveness (Lieberman 2007; Gaynes et al. 2009; Stein et al. 2006; Fredriksen et al. 2013;
Ling et al. 1998). Results are reported in Table 6.
As expected, anti-depressants and anti-anxiety medications were the most common
prescriptions in the pre-expansion period: 2,996 and 2,616 per 100,000 per quarter. The
quarterly number of prescriptions for anti-psychotic medications, mood stabilizers, and
stimulants per 100,000 was 2,061; 1,212; and 847 respectively. Medicaid expansion increased
prescriptions for anti-depressants, anti-anxiety, anti-psychotic, and stimulant medications by
1,077 (35.9%), 623 (23.8%), 251 (12.2%), and 146 (17.2%) per 100,000 non-elderly per quarter
post-expansion in expansion states relative to non-expansion states. We find no statistically
significant evidence that mood stabilizer prescriptions were altered by the expansions, although
the coefficient estimate is positive and implies a 6.4% increase. These findings suggest that anti-

15

depressant prescriptions and anti-anxiety medications were more responsive to the expansions
than other medication classes. This pattern of results is in line with the fact that these illnesses
are relatively common among Medicaid enrollees and are more likely to be treated in nonspecialty settings. 13 While the point estimates and relative effect sizes do vary across
psychotropic class, we note that confidence intervals surrounding the specific medication point
estimates overlap.
4.4 Differences-in-differences regressions: Prescription costs of Medicaid expansions
We next construct total and Medicaid payments for the psychotropic medications so that
we can study the costs of increased psychotropic medications post-expansion. We also examine
the extent to which state Medicaid programs, and not patients, financed the increased
prescriptions. We convert payments to 2017 terms using the Consumer Price Index. We
consider overall costs of these medications and control for the state population age 18 to 64 years
in all payment regressions. To account for dependent variable skewness, we estimate
generalized least squares models with a Poisson link selected using a modified Park test for
healthcare cost data outlined by Manning and Mullahy (2001). 14 Results are reported in Table 7.
Our cost estimates are overestimated because the SDUD does not include state rebates
from pharmaceutical companies participating in the Medicaid Rebate Program. Government
estimates just prior to the ACA suggest that states recoup roughly 45% of their payments in the
form of rebates (Levinson 2011). 15 Our estimates of the effect of expanding Medicaid on costs
can be scaled by this number to reduce measurement error. In addition to rebates paid to states

13
We note that anti-psychotics have been increasingly used to treat depression in primary care settings (Wright,
Eiland, and Lorenz 2013), which may explain the rise in these prescriptions in primary care settings.
14
Details available on request.
15
We were not able to locate a more recent estimate. Data on rebates is not easily assessable to the public. More
details are available on request.

16

through the Medicaid Rebate Programs, many states directly negotiate with pharmaceutical
companies for supplemental rebates. If states, by expanding Medicaid, were better able to
negotiate for supplemental rebates then we will be unable to separate expansion effects (e.g.,
increased utilization of services) from negotiation effects (e.g., higher rebates).
We find that, post-expansion, total pre-rebate payments increased by $4.2M per quarter
in expansion states relative to non-expansion states; Medicaid pre-rebate payments increased by
$4.0M. 95% confidence surrounding these point estimates overlap. Compared to the pre-ACA
mean in expansion states, these estimates translate to a 9.7% increase in total payments and a
9.4% increase in Medicaid payments. If we assume that state Medicaid programs received
rebates that accounted for 45% of psychotropic payments, then the corrected increase in
Medicaid payments attributable to the expansion was $2.2M per quarter. Given the similarity in
the total and Medicaid coefficient estimates, we assume that Medicaid, and not patients, provided
the vast majority of the expansion-attributable prescriptions. This finding is arguably not
surprising given the federally regulated low cost-sharing levels in Medicaid.
The estimated relative increase in prescriptions (22.3%) is larger than the estimated
relative increase in payments (9.4%). For comparison, by the end of our study period (Q2 2017),
total Medicaid enrollment increased by 30% over the pre-ACA baseline (Kaiser Family
Foundation 2018). To explore whether this difference in effect size is driven by prescribing
patterns, we estimate two auxiliary regressions using Equation (1): (i) the ratio of total payments
to the number of pills dispenses (a proxy for price) and (ii) the number of pills per prescription (a
proxy for dosage). The purpose of estimating these regressions is to examine whether Medicaid
expansion leads to changes in the types of medications prescribed (e.g., less costly medications)
and/or doses (e.g., more pills per prescription). We report results in Table 8.

17

We find no statistically significant evidence that Medicaid expansion lead to changes in
these variables in expansion states relative to non-expansion states. While we cannot test this
hypothesis as data on supplemental rebates are â€“ to the best of our knowledge â€“ not publically
available, we postulate that states ability to better negotiate with pharmaceutical companies for
supplemental rebates allows them to offset some of the prescription costs or reduced costs
through some other means. Moreover, if we compare the tails of our 95% confidence intervals
surrounding these estimates the implied increases are more similar. For example, the bottom tail
of the 95% confidence interval surrounding the prescription medication estimate implies a 14.0%
increase while the top tail of the 95% confidence interval surrounding the Medicaid payment
estimate implies a 16.9% increase in payments.
5. Extensions and robustness
We next explore heterogeneity in Medicaid effects across state characteristics, probe the
stability of our findings through a number of robustness checks, and investigate the effects of
Medicaid expansion on a measure of serious mental illness: suicide.
5.1 Heterogeneity across state characteristics
Medication expansion effects may vary across state features, for example patient need for
mental illness treatment, access to primary care, mental illness co-morbidities, and uninsurance.
These characteristics plausibly reflect differences in the potential benefits to states from
Medicaid expansion and capacity of statesâ€™ healthcare delivery systems to support a large-scale
insurance expansion. Documenting such heterogeneity is important for policymakers in the
states that have not expanded Medicaid in determining whether expanding could benefit their
constituents and for considering the distributional effects of a large policy shift across states.

18

We explore such heterogeneity by estimating separate regressions for states at/above and
below the national median for (i) prevalence of serious mental illness among adults from the
NSDUH, (ii) uninsurance rate among adults 18 to 64 from the American Community Survey
(Ruggles et al. 2017), 16 (iii) ratio of primary care doctors to Medicaid beneficiaries using data
from the Area Health Resource File and CMS, and (iv) adult smoking rates from the Centers for
Disease Control and Preventionâ€™s Behavioral Risk Factor Surveillance Survey. 17 We use 2010
data to construct these variables to avoid stratifying our sample on an endogenous variable.
Results are reported in Appendix Tables 1 (treatment need), 2 (uninsurance), 3 (primary
care access), and 4 (smoking). While point estimates do vary across samples, 95% confidence
intervals overlap, suggesting that the effects of Medicaid expansion were relatively homogenous
across state characteristics. For example, in states with above the median mental illness
prevalence the increase in prescriptions was 2,297 per quarter and in states with below the
median mental illness prevalence the increase was 1,736; but 95% confidence intervals overlap.
5.2 Policy endogeneity
State policies are determined by the political economy within the state. An important
empirical concern is therefore reverse causality. For example, state legislatures, concerned with
rising mental illness or other related factors, may implement policies, such as the decision to
expand Medicaid, in an attempt to reverse these trends. Such a phenomena implies that
outcomes may induce changes in policies rather than policies inducing changes in outcomes.

16

We rely on public use NSDUH data from 2009/2010. Our proxy is: â€˜Serious mental illness (SMI) is defined as
having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use
disorder, that met the criteria found in the 4th edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) and resulted in serious functional impairment.â€™
17
Smoking is highly correlated with mental illness. Adults with mental illness consume 30% of all cigarettes in the
U.S. (Substance Abuse and Mental Health Services Administration 2013) .

19

We estimate an event study to examine reverse causality following Autor (2003). We
include a series of variables for each time period before and after expansion (policy leads and
lags) in Equation (1). These lead and lag variables are constructed by interacting each period
indicator with an indicator for expansion states. 18 We set Q4 2013 as the index period. Statespecific linear time trends are excluded from the event study following Wolfers (2006). In
particular, Wolfers notes that models with dynamics (such as the leads and lags in an event
study) should not include state-specific trends as such trends can muddle interpretation of the
estimates of dynamic effects. We drop states with substantial expansions before 2011. Results
are presented graphically in Figure 2. We report the coefficient estimates and associated 95%
confidence intervals that account for within-state clustering for each lead/lag.
The event studies do not reveal evidence of reverse causality: the coefficient estimates on
the leads are small and imprecise, and alternate in sign. Post-expansion the estimated
coefficients are positive and precise. The event study results suggest that increases in
prescriptions increased over time. This pattern of results is not surprising as the newly eligible
must take up Medicaid and make an appointment with a provider prior to filling a prescription. 19
5.3 Weighting
We estimated unweighted regressions, however, the economics field has not yet reached
consensus regarding the use of weights in analyses seeking to estimate causal effects (Angrist
and Pischke 2009; Solon, Haider, and Wooldridge 2015). Given the lack of consensus, we reestimate Equation (1) using the state population ages 18 to 64 years as weights. Weighted results
are reported in Appendix Table 5 and are not appreciably different from unweighted results.

18

Coded one if the state expanded Medicaid during our study period and zero otherwise (Lovenheim 2009).
Another concern in policy analyses is program induced migration (Moffitt 1992). To the best of our knowledge,
Medicaid expansion did not induce such behavior (Goodman 2017).

19

20

5.4 Controlling for between-state heterogeneity
A critical concern in differences-in-differences analyses is adequately accounting for
between-state differences. In Equation (1) we use state fixed effects and state-specific linear
period time trends. However, this specification imposes a specific structure on the
unobservables that may be incorrect. On the other hand, if there are no important state-level
unosbervables, then Equation (1) throws away variation that could be used for identification.
We next probe the sensitivity of our results to alternative approaches to controlling for
between-state heterogeneity. Specifically, we rely on (i) state- and period-fixed effects, (ii) statespecific quadratic time trends, (iii) state-by-year fixed effects, and (iv) state-specific linear time
trends and a larger set of state time-varying characteristics from the CPS (poverty rate, 20 Veteran
status, marital status, family size, number of children in the family, work-limiting disability, and
any activity limitation). Results are reported in Appendix Table 6 and are not appreciably
different from our main findings and 95% confidence intervals generally overlap.
5.5 Alternative coding schemes for Medicaid expansion
There are several alternative Medicaid expansion coding schemes used in the literature
(Frean, Gruber, and Sommers 2017; Simon, Soni, and Cawley 2017; Wherry and Miller 2016).
Our review of these coding schemes suggests that there is little disagreement in terms of what
states expanded Medicaid, but rather what states had expanded Medicaid prior to 2014. To
assess the extent to which our findings are driven by a particular coding scheme, we also test
alternative approaches to coding ACA Medicaid expansion. Specifically, we re-estimate
Equation (1) using the following coding schemes: (i) we drop states with substantial pre-2011

20

We note that there was a change in the CPS income questions over our study period (Czajka and Rosso 2015)
which may affect the poverty rate measurement. We have estimated region models without the poverty rate, but
with other controls in the long covariate set, and results are very similar.

21

expansions following Wherry and Miller (2016), and (ii) we use a coding scheme outlined in
Maclean and Saloner (2017). We also drop California and re-estimate Equation (1) to ensure
that our results are not driven by a large state with a strong pre-ACA Medicaid presence. Results
are broadly robust to the use of these alternative coding schemes and are reported in Appendix
Table 7. Indeed, 95% confidence intervals surrounding the point estimate overlap
5.6 Isolating effects for the newly eligible from other Medicaid populations
Equation (1) relies on variation in statesâ€™ decision to expand Medicaid to newly eligible
populations, but this design may confound newly eligible effects with effects for other groups
that enrolled in Medicaid with the ACA (i.e., welcome mat effects and MAGI effects). We next
explore whether our main findings are reasonable estimates for the newly eligible.
First, we estimate a triple-difference style model that leverages changes in the newly
eligible enrollees using CMS Medicaid enrollment data; we exclude 2017 from this analysis as
enrollment data by newly eligible status was not available at the time of writing. We augment
Equation (1) with an interaction between an indicator for an expansion state, the post period (this
variable varies across expansion states depending on when they expanded Medicaid; for nonexpansion states this period is 2014 to 2016), and the newly eligible as a percent of increased
enrollment. The newly eligible share of increased enrollment between 2013 and each period is
defined as follows:
(3)

ğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  = ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡

ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ ğ‘ ğ‘ ğ‘ 

ğ‘ ğ‘ ğ‘ ğ‘  âˆ’ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘ ğ‘ ,2013

âˆ— 100%

Where ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ ğ‘ ğ‘ ğ‘  is the number of newly eligible enrollees in state s in period t, ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘ ğ‘ ğ‘ ğ‘  is the total

number of enrollees in state s in time t, and ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘ ğ‘ ,2013 is the total number of enrollees in state s
in 2013 (the year before the Medicaid expansion). This variable is coded as zero in all years

prior to expansion for expansion states and for non-expansion states in all periods. We constrain
22

ğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  to lie between 0% and 100% in all years 21 and exclude early expanding states from

this analysis. The Medicaid expansion indicator captures the effect of Medicaid expansion on all
Medicaid enrollees other than the newly eligible (welcome mat and MAGI effects) and the three-

way interaction captures the effect for the newly eligible. We do not include the main effect for
ğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  as it is collinear with other variables in the regression. We note that the ğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  is

obviously influenced by whether or not a state expands Medicaid, which implies that results
generated in this specification are likely vulnerable to over-controlling bias.

Results are reported in Appendix Table 8. The coefficient on the expansion variable,
which captures effects for previously eligible and those individuals who gained eligibility
through MAGI changes, is 1,011 and implies that prescriptions increased 10.4% per quarter
within these groups in expansion states relative to non-expansion states in the post-expansion
period. The coefficient estimate on the three-way interaction, which captures effects for the
newly eligible, is precise and positive: 12. As a way of interpreting this coefficient estimate, we
multiply it by the mean value of ğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  in the post-expansion period among expansion states
(74.3%). Based on this calculation, we find that, post-expansion, prescriptions among newly
eligible populations increased by 891 per 100,000 non-elderly residents each quarter (9.2%).
Given the similarity between the two estimates, we cannot rule out the possibility that increases
in prescriptions between the newly eligible and other groups that enrolled in Medicaid due to
ACA-related changes are the same. Indeed, the 891 estimate for the newly eligible lies within
the 95% confidence for the non-newly eligible. Moreover, examination of the top tail of the 95%

We set ğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  to zero for a few states that had declines in total enrollment, perhaps due to the improving
economy over the study period. We capped ğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ƒğ‘ ğ‘ ğ‘ ğ‘  at 100%, because, in readily available CMS enrollment
summaries, early expansion enrollees were reclassified in 2014 as newly eligible, implying that the newly eligible
grew more than total enrollment.
21

23

confidence intervals suggest increases of 21.6% and 16.8% for non-newly eligibles and newly
eligibles respectively which are in line with our main point estimates.
Next, we focus on Medicaid managed care prescriptions rather than prescriptions from
both managed care and fee-for-service programs combined as we do in our main analysis
because most newly eligibles are enrolled in managed care plans while traditional populations
are more likely to be enrolled in fee-for-service plans (Kaiser Commission on Medicaid and the
Uninsured 2016). Over 80% of newly eligible enrollees are covered by managed care in most
expansion states, and over 90% in some states (Paradise 2017). We include an interaction
between the Medicaid expansion indicator and an indicator for managed care-financed
prescriptions and re-estimate Equation (1); with the unit of observation being a state-yearquarter-program (managed care vs. fee-for-service). Sample sizes are not double our main
sample size as not all states report managed care and fee-for-service data in all years (e.g., some
states do not have managed care programs in some years). Details available on request.
Results are reported in Appendix Table 9. The coefficient estimate on Medicaid
expansion is imprecise and wrong-signed (negative). However, the interaction term estimate
(expansion interacted with managed care) is positive, precise, and large in magnitude. We
interpret these findings to imply that increased prescriptions predominately occurred within
managed care Medicaid and not fee-for-service Medicaid. Given that the newly eligible are
substantially more likely to be enrolled in managed care, these findings imply that our main
effects are likely attributable to the newly eligible.
Considering our approaches to isolate effects for the newly eligible from other
populations that enrolled in Medicaid concurrent with the ACA roll-out suggests that our main
effects are not fully attributable to other groups. Our findings from these analyses are in line

24

with recent work by Biener, Zuvekas, and Hill (2017). The authors show that, post-expansion,
primary care visits increased among newly-eligibles but such visits were not altered among
previously eligibles. Of relevance to our work, primary care settings are a likely location from
which a psychotropic medication prescription may originate. Overall, we find no evidence to
suggest that our main point estimates do not offer a reasonable estimate for the newly eligble.
5.7 Mental illness
Thus far in the analysis we have examined the effect of Medicaid expansion on
psychotropic medications and our results provide convincing evidence that prescriptions for
these medications increased post-expansion. However, we are also interested in the effects of
Medicaid expansion on mental illness. To explore such effects, we turn to the National Vital
Statistics System (NVSS). The NVSS provides the universe of deaths in the U.S. and lists the
underlying cause of death. We use this information to calculate the quarterly number of suicides
among adults 18 to 64 years in each state in our sample between 2011 and 2016 (public use data
for 2017 was not available at the time of writing). We convert the number of suicides to the rate
per 100,000 non-elderly adults each quarter in each state. We match Medicaid expansion dates
to the NVSS using the same procedure outlined for the SDUD. We estimate Equations (1), DD,
and (2), parallel trends, in the NVSS. Results are reported in Appendix Table 10. Our parallel
trends testing provides suggestive evidence that the NVSS data are able to satisfy the parallel
trends assumption. We find no statistically significant evidence that suicides declined in
expanding states relative to non-expanding states in the post-expansion period. However, we
note that suicides are a relatively rare outcome and that previous investigations into Medicaid
effects imply that other measures of mental health have improved post-expansion.
6. Discussion

25

Lower income populations are at elevated risk for mental illness and are less likely to
have insurance. Public insurance expansions can allow such populations to obtain insurance
coverage and, in turn, receive effective treatment for mental illness. We examine the effect of a
large-scale and recent public insurance expansion that covered mental illness services and
prescription medications in the U.S. Specifically, we leverage within-state variation in Medicaid
eligibility generated by provisions in the ACA over the period 2011 to 2017 to study changes in
Medicaid-financed prescriptions for psychotropic medications obtained in outpatient, nonspecialty settings.
We find that post-expansion the number of Medicaid-financed psychotropic prescriptions
increased by 22.3% in expanding states relative to non-expanding states. For comparison, by the
end of our study period (Q2 2017), total Medicaid enrollment increased by 30% relative to the
pre-ACA baseline (Kaiser Family Foundation 2018). The increases in prescriptions were
observed across nearly all classes of psychotropic medications and effects were relatively
homogeneously experienced across state characteristics that proxy for patient need, system
capacity, and expansion scope. The costs of increased psychotropic prescriptions for state
Medicaid programs were $2.2M per quarter, which translates to $30.8M for states that expanded
Medicaid January 1st, 2014. Medicaid, and not patients, financed these costs. An event study
shows that expansion effects increased with time, suggesting that the newly eligible with mental
illness were able to maintain relationships with primary care providers and manage their
illnesses. Given cognitive and social challenges faced by many with mental illness, this pattern
was not obvious ex ante. We provide suggestive evidence that our findings reflect changes in
prescribing patterns among the newly eligible and cannot be fully explained by changes in
prescribing experienced by other populations that enrolled in Medicaid due to ACA changes

26

more broadly (e.g., welcome mat effects). Finally, we do not find evidence that Medicaid
expansion altered suicide rates. However, suicides likely reflect serious mental illness and it
may take time for Medicaid to alter such outcomes.
Our findings contribute to the growing literature investigating the effects of the ACArelated Medicaid expansions. In line with previous research we show that these expansions
increased use of healthcare services (Ghosh, Simon, and Sommers 2017; Sommers et al. 2016;
Miller and Wherry 2017; Wherry and Miller 2016; Maclean, Pesko, and Hill 2017; Wen et al.
2017). Simon, Soni, and Cawley (2017) and Winkelman and Chang (2017) show that selfassessed health, which is believed to capture aspects of mental health (Horn, Maclean, and Strain
2017), improved within expanding states. Our findings suggest that increased access to
psychotropic medications may provide evidence on one potential pathway through which the
expansion lead to improved self-assessed health. Other factors, for example reduced financial
strain (Hu et al. 2016), likely play a role in Medicaid-related mental health promotion as well.
Policymakers and providers have historically been concerned that mental healthcare
demand is more price-elastic than other forms of healthcare, suggesting that expanding coverage
for these services will lead to unsustainable costs healthcare (Frank and McGuire 2000).
Interestingly, within the context of ACA-related Medicaid expansions, we find that increases in
psychotropic medication prescriptions were smaller than increases in prescriptions for smoking
cessation (36%) and substance use disorder prescriptions (55% to 70%) (Maclean and Saloner
2017; Maclean, Pesko, and Hill 2017; Wen et al. 2017), but were similar to increases in overall
prescriptions (19%) (Ghosh, Simon, and Sommers 2017).
Our study has limitations. (i) We lack data on patients and providers, and cannot explore
issues such as whether the medicine was prescribed appropriately and if it improved mental

27

illness-related outcomes. (ii) The SDUD does not include manufacturer rebates to states and
thus we have error in our payment variables. We have used government estimates on the size of
Medicaid rebates to states (U.S. Department of Health and Human Services 2012) to scale our
cost estimates which may mitigate some error. (iii) We have information on a single payer.
Our analysis suggests that public insurance expansions allow low-income individuals
with mental illnesses to access valuable healthcare services. Reforms that curtail such access
could worsen health outcomes for such individuals and, given the established negative
externalities associated with mental illness (Insel 2008), have implications for broader society in
terms of crime, increased healthcare costs, a less productive workforce, and so forth.
Policymakers may wish to consider these costs to society when framing the future of Medicaid.

28

Table 1. Psychotropic medications
Class:
Medications
Antidepressant
Aplenzin, Budeprion, Bupropion, Celexa, Citalopram, Cymbalta, Duloxetine,
Effexor, Escitalopram, Fluoxetine, Forfivo, Lexapro, Paroxetine, Paxil, Pexeva,
Prozac, Rapiflux, Sarafem, Selfemra, Sertraline, Venlafaxine, Wellbutrin, and Zoloft.
Anti-anxiety
Alprazolam, Ativan, Buspar, Buspirone, Clonazepam, Klonopin, Lorazepam,
Niravam, and Xanax.
Anti-psychotic
Abilify, Aripiprazole, Chlorpromazine, Clozapine, Clozaril, Etrafon, Fazaclo,
Fluphenazine, Geodon, Haldol, Haloperidol, Invega, Latuda, Lurasidone, Olanzapine,
Paliperidone, Perphenazine, Permitil, Prolixin, Quetiapine, Risperdal, Risperidone,
Seroquel, Symbyax, Thorazine, Trilafon, Triavil, Ziprasidone, and Zyprexa.
Mood stabilizer
Depakene, Depakote, Divalproex sodium, Eskalith, Lamictal, Lamotrigine, Lithane,
Lithium, Lithobid, Stavzor, Valproate sodium, and Valproic acid.
Stimulant
Adderall, Amphetamine, Aptensio, Concerta, Dexedrine, Dextroamphetamine,
Dextrostat, Lisdexamfetamine, Metadate, Methylin, Methylphenidate, Procentra,
Quillichew, Quillivant, Ritalin, and Vyvanse.
Notes: Data source is National Institute of Mental Health: https://www.nimh.nih.gov/health/topics/mental-healthmedications/index.shtml and Medline websites (https://www.medline.com/) for specific medications (e.g., Aplenzin)
embedded in the website (both websites accessed June 10th, 2017). Overall psychotropic medications include the
union of the classes listed in this table. More details available on request from the corresponding author.

29

Table 2. State Medicaid eligibility expansions
State:
Medicaid expansion date
States with substantial expansions before 2011
Delaware
Before 2011
District of Columbia
Before 2011
Massachusetts
Before 2011
New York
Before 2011
Vermont
Before 2011
States with substantial expansions in 2011-2014
Arizona a,b
1/1/2014
Arkansas
1/1/2014
California c
1/1/2014
Colorado
1/1/2014
Connecticut d
1/1/2014
Hawaii b
1/1/2014
Illinois
1/1/2014
Iowa
1/1/2014
Kentucky
1/1/2014
Maryland
1/1/2014
Michigan
4/1/2014
Minnesota d
1/1/2014
Nevada
1/1/2014
New Hampshire
8/15/2014
New Jersey d
1/1/2014
New Mexico
1/1/2014
North Dakota
1/1/2014
Ohio b
1/1/2014
Oregon
1/1/2014
Rhode Island b
1/1/2014
Washington e
1/1/2014
West Virginia
1/1/2014
Late expansion states (post-2014)
Alaska
9/1/2015
Indiana
2/1/2015
Montana f
1/1/2016
Louisiana f
7/1/2016
Pennsylvania
1/1/2015
Notes: Medicaid expansion dates derived from Simon et al. (2017). â€˜Substantialâ€™ expansions covered both parents
and childless adults up to at least 100% FPL, were open to new enrollees, and had full Medicaid benefits. Maine
adopted the Medicaid expansion through a ballot initiative in November 2017, but at the time of writing an effective
date for the expansion had not been announced.
a
Expanded eligibility prior to 2011 but closed to new enrollees in 2011.
b
Excluded, with Virginia, from the analysis due to data quality issues.
c
From 2011 through 2013, some but not all California counties expanded eligibility, and income eligibility
thresholds varied by county.
d
Expanded eligibility prior to 2014 but with low eligibility thresholds.
e
Expanded eligibility prior to 2014 but only to people who had previously enrolled in a state program.
f
Non-expansion during the entire study period, 2011-2015.

30

Table 3. Summary statistics for expansion and non-expansion states: SDUD 2011-2013
Expansion
Non-expansion
Difference
Sample:
states
states
(p-value)*
Mental illness prescriptions per 100,000
Prescriptions
9,731
9,068
0.0516
State-year level characteristics
Unemployment rate (18 to 64 years)
0.06
0.071
0.0053
Age
37.76
37.24
0.0001
Female
0.492
0.490
0.0109
Male
0.508
0.510
0.0109
White
0.807
0.799
0.4755
African American
0.087
0.135
0.0000
Other race
0.107
0.065
0.0000
Hispanic
0.120
0.093
0.0050
Born outside the U.S.
0.106
0.077
0.0000
Less than high school
0.324
0.340
0.0000
High school
0.237
0.238
0.7693
Some college
0.226
0.230
0.0369
College degree
0.214
0.193
0.0000
Observations
308
216
-Notes: Unit of observation is the state-year-quarter. States with substantial expansions before 2011 excluded from
the analysis (see Table 2).
*Two-tailed t-tests applied.

31

Table 4. Parallel trends test for psychotropic medication prescriptions per 100,000 non-elderly: SDUD 20112013
Outcome:
Prescriptions
Mean value in expansion states, pre-expansion
9,731
Treat * trend
-30
[-124; 64]
Observations
524
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, and state and period fixed effects.
95% confidence account for within-state clustering and are reported in square brackets. States with substantial
expansions before 2011 excluded from the analysis (see Table 2).
***,**,* = statistically different from zero at the 1%,5%,10% level.

Table 5. Effect of Medicaid expansion on psychotropic medication prescriptions per 100,000 non-elderly
using differences-in-differences models: SDUD 2011-2017
Outcome:
Prescriptions
Mean value in expansion states, pre-expansion
9,731
Expansion
2,174***
[1,367; 2,981]
Observations
1,270
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets.
***,**;* = statistically different from zero at the 1%,5%, 10% level.

32

Table 6. Effect of Medicaid expansion on psychotropic medication prescriptions per 100,000 non-elderly
using differences-in-differences models: SDUD 2011-2017
Outcome:
Prescriptions
Mean value for anti-depressant medications in expansion states,
2,996
pre-expansion
Anti-depressant medications
1,077***
[674; 1,480]
Mean value for anti-anxiety medications in expansion states, pre2,616
expansion
Anti-anxiety medications
623***
[390; 855]
Mean value for anti-psychotic medications in expansion states, pre2,061
expansion
Anti-psychotic medications
251***
[133; 369]
Mean value for mood stabilizer medications in expansion states,
1,212
pre-expansion
Mood stabilizer medications
78
[-22; 178]
Mean value for stimulant medications in expansion states, pre847
expansion
Stimulant medications
146***
[87; 204]
Observations
1,270
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets.
***,**;* = statistically different from zero at the 1%,5%, 10% level.

33

Table 7. Effect of Medicaid expansion on psychotropic medication prescription payments ($1,000s) using
differences-in-differences models: SDUD 2011-2017
Total
Medicaid
Outcome:
payments
payments
Mean value for all medications in expansion states, pre$43,551
$42,349
expansion
All medications
4,244***
3,992**
[1,131; 7,357]
[817; 7,166]
Observations
1,270
1,270
Notes: Unit of observation is the state-year-quarter. All models estimated with a GLM model and control for state
demographics, state population ages 18 to 64 years, state and period fixed effects, and state-specific linear time
trends. Average marginal effects reported. 95% confidence account for within-state clustering and are reported in
square brackets.
***,**,* = statistically different from zero at the 1%,5%, 10% level.

Table 8. Effect of Medicaid expansion on psychotropic medication prices using differences-in-differences
models: SDUD 2011-2017
Outcome:
Price per pill
Pills/prescription
Mean value in expansion states, pre-expansion
$14.78
263
Expansion
1
-4
[-1; 3]
[-8; 1]
Observations
1,270
1,270
Notes: Price is defined as the ratio of total payments to pills. Unit of observation is the state-year-quarter. All
models estimated with OLS and control for state demographics, state population ages 18 to 64 years, state and
period fixed effects, and state-specific linear time trends. 95% confidence account for within-state clustering and
are reported in square brackets.
***,**;* = statistically different from zero at the 1%,5%, 10% level.

34

Appendix Table 1. Heterogeneity in Medicaid expansion effects on psychotropic medication prescriptions per
100,000 non-elderly by need for mental illness healthcare using differences-in-differences models: SDUD
2011-2017
Outcome:
Prescriptions
Sample: High mental illness care need states
Mean value in expansion states, pre-expansion
10,327
Expansion
2,297***
[1,062; 3,532]
Observations
650
Sample: Low mental illness care need states
Mean value in expansion states, pre-expansion
8,893
Expansion
1,736***
[744; 2,728]
Observations
620
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets. Need for mental illness treatment calculated using National Survey of Drug Use and Health 2009/2010
state-level data.
***,**,* = statistically different from zero at the 1%,5%, 10% level.

Appendix Table 2. Heterogeneity in Medicaid expansion effects on psychotropic medication prescriptions per
100,000 non-elderly by uninsurance rate using differences-in-differences models: SDUD 2011-2017
Outcome:
Prescriptions
Sample: High uninsurance rate states
Mean value in expansion states, pre-expansion
9,499
Expansion
2,525***
[1,372; 3,677]
Observations
676
Sample: Low uninsurance rate states
Mean value in expansion states, pre-expansion
10,010
Expansion
1,764***
[612; 2,916]
Observations
594
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets. Uninsurance rates calculated using the American Community Survey 2010 data.
***,**,* = statistically different from zero at the 1%,5%,10% level.

35

Appendix Table 3. Heterogeneity in Medicaid expansion effects on psychotropic medication prescriptions per
100,000 non-elderly by access to primary care using differences-in-differences models: SDUD 2011-2017
Outcome:
Prescriptions
Sample: High primary care access states
Mean value in expansion states, pre-expansion
8,634
Expansion
2,417***
[1,495; 3,339]
Observations
620
Sample: Low primary care access states
Mean value in expansion states, pre-expansion
11,194
Expansion
1,918***
[503; 3,332]
Observations
650
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets. Access to primary care calculated using CMS and Area Resource File 2010 data.
***,**,* = statistically different from zero at the 1%,5%, 10% level.

Appendix Table 4. Heterogeneity in Medicaid expansion effects on psychotropic medication prescriptions per
100,000 non-elderly by smoking status using differences-in-differences models: SDUD 2011-2017
Outcome:
Prescriptions
Sample: High smoking rate states
Mean value in expansion states, pre-expansion
10,722
Expansion
2,359***
[1,307; 3,411]
Observations
676
Sample: Low smoking rate states
Mean value in expansion states, pre-expansion
8,714
Expansion
1,715***
[635; 2,796]
Observations
594
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets. Smoking rates calculated using Behavioral Risk Factor Surveillance Survey 2010 data.
***,**,* = statistically different from zero at the 1%,5%,10% level.

36

Appendix Table 5. Effect of Medicaid expansion on psychotropic medication prescriptions per 100,000 nonelderly using differences-in-differences models using population weights: SDUD 2011-2017
Outcome:
Prescriptions
Weighted mean value in expansion states, pre-expansion
9,287
Expansion
1,687***
[906; 2,468]
Observations
1,270
Notes: State populations ages 18 to 64 years serve as the weights. Unit of observation is the state-year-quarter. All
outcomes are converted to a rate per 100,000 persons 18 to 64 years. All models are estimated with OLS and
control for state demographics, state and period fixed effects, and state-specific linear time trends. 95% confidence
account for within-state clustering and are reported in square brackets.
***,**,* = statistically different from zero at the 1%,5%,10% level.

Appendix Table 6. Effect of Medicaid expansion on psychotropic medication prescriptions per 100,000 nonelderly using differences-in-differences models with different controls for between-state differences: SDUD
2011-2017
Outcome:
Prescriptions
Mean value in expansion states, pre-expansion
9,731
Model (1)
3,031***
[2,013; 4,049]
Model (2)
1,874***
[1,018; 2,729]
Model (3)
1,624*
[-226; 3,474]
Model (4)
1,935***
[1,119; 2,751]
Observations
1,270
Notes: The outcome variable in each regression is the number of prescription fills and refills. Unit of observation is
the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to 64 years. All models
estimated with OLS. 95% confidence account for within-state clustering and are reported in square brackets. Model
(1) controls for state demographics, and state and period fixed effects. Model (2) controls for state demographics,
state and period fixed effects, and state-specific quadratic time trends. Model (3) controls for state demographics,
quarter fixed effects, and state-by-year fixed effects. Model (4) controls for an extended set of state demographics
(see text), state and period fixed effects, and state-specific linear time trends.
***,**,* = statistically different from zero at the 1%,5%,10% level.

37

Appendix Table 7. Effect of Medicaid expansion on psychotropic medication prescriptions per 100,000 nonelderly using differences-in-differences models using alternative Medicaid expansion coding schemes: SDUD
2011-2017
Outcome:
Prescriptions
Mean value in expansion states, pre-expansion
9,731
Wherry & Miller exclusions
2,195***
[1,381; 3,010]
Observations
1,140
Mean value in expansion states, pre-expansion
10,744
Maclean & Saloner coding scheme
1,718***
[851; 2,585]
Observations
1,270
Mean value in expansion states, pre-expansion
9,898
Exclude California
2,184***
[1,356; 3,013]
Observations
1,244
Notes: Unit of observation is the state-year-quarter. See text for a discussion of the alternative Medicaid expansion
coding schemes. All outcomes are converted to a rate per 100,000 persons 18 to 64 years. All models are estimated
with OLS and control for state demographics, state and period fixed effects, and state-specific linear time trends.
95% confidence account for within-state clustering and are reported in square brackets.
***,**;* = statistically different from zero at the 1%,5%, 10% level.

Appendix Table 8. Effect of Medicaid expansion on psychotropic medication prescriptions per 100,000 nonelderly using a triple difference-style estimator: 2011-2016
Outcome:
Prescriptions
Mean value in expansion states, pre-expansion
9,731
Expansion * post
1,011*
[-87; 2,109]
Expansion * post * percent
12**
[2; 22]
Mean percent, treatment group, post-expansion period:
74.27
Observations
1,052
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets. Expansion = an indicator for expansion in state. Post = an indicator for the period after expansion.
Percent = newly eligible enrollees as a percent of Medicaid enrollment increase between 2013 in state s and period t.
States with substantial expansions before 2011 excluded from the analysis (see Table 2).
***,**,* = statistically different from zero at the 1%,5%,10% level.

38

Appendix Table 9. Effect of Medicaid expansion on psychotropic medication prescriptions per 100,000 nonelderly using differences-in-differences and allowing and heterogeneity by Medicaid program type: 2011-2017
Outcome:
Prescriptions
Mean value in expansion states, pre-expansion
5,947
Expansion
-476
[-2,005; 1,052]
Expansion * managed care program
4,074***
[1,130; 7,018]
Managed care program
-2,423*
[-4,923 ;77]
Observations
2,114
Notes: Unit of observation is a state-year-quarter-Medicaid program (managed care vs. fee-for-service). Only
observations with both managed care and fee-for-service included in the analysis sample. All outcomes are
converted to a rate per 100,000 persons 18 to 64 years. All models are estimated with OLS and control for state
demographics, state and period fixed effects, and state-specific linear time trends. 95% confidence account for
within-state clustering and are reported in square brackets.
***, **, and * = statistically different from zero at the 1%, 5%, and 10% level.

Appendix Table 10. Effect of Medicaid expansion on suicides per 100,000 non-elderly using differences-indifferences models: NVSS 2011-2016
Outcome:
Suicides
Mean value in expansion states, pre-expansion
4.75
Parallel trends test
-0.02
[-0.05,0.02]
Observations
552
Differences-in-differences
0.15
[-0.07,0.37]
Observations
1,224
Notes: Unit of observation is the state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to
64 years. All models are estimated with OLS and control for state demographics, state and period fixed effects, and
state-specific linear time trends. 95% confidence account for within-state clustering and are reported in square
brackets.
***,**;* = statistically different from zero at the 1%,5%, 10% level.

39

80
20
00
11
20 Q
11 1
20 Q
11 2
20 Q
11 3
20 Q
1 4
20 2 Q
12 1
20 Q
1 2
20 2 Q
12 3
20 Q
1 4
20 3 Q
13 1
20 Q
1 2
20 3 Q
13 3
20 Q
1 4
20 4 Q
14 1
20 Q
14 2
20 Q
14 3
20 Q
1 4
20 5 Q
15 1
20 Q
1 2
20 5 Q
15 3
20 Q
1 4
20 6 Q
16 1
20 Q
1 2
20 6 Q
16 3
20 Q
1 4
20 7 Q
17 1
Q
2

10
00
0

12
00
0

14
00
0

Figure 1. Trends in all psychotropic medication prescriptions per 100,000 non-elderly in expansion and nonexpansion states: SDUD 2011-2017

Expansion
Non-expansion

Notes: Data is aggregated to the treatment-period level.

40

20
Q 11
3
20
Q 11
4
20
Q 11
1
20
Q 12
2
20
Q 12
3
20
Q 12
4
20
Q 12
1
20
Q 13
2
20
Q 13
3
20
Q 13
1
20
Q 14
2
20
Q 14
3
20
Q 14
4
20
Q 14
1
20
Q 15
2
20
Q 15
3
20
Q 15
4
20
Q 15
1
20
Q 16
2
20
Q 16
3
20
Q 16
4
20
Q 16
1
20
Q 17
2
20
17

Q
2

Q
1

20

11

-2000

0

2000

4000

6000

Figure 2. Effect of Medicaid expansions on psychotropic medication prescriptions per 100,000 non-elderly
using an event study model: SDUD 2011-2017

Notes: Unit of observation is a state-year-quarter. All outcomes are converted to a rate per 100,000 persons 18 to 64
years. Event study dummy variables include each year-quarter cell between Q1 2011 and Q2 2017, the omitted
category is Q4 2013. All models are estimated with OLS and control for state demographics, and state and period
fixed effects. 95% confidence intervals account for state-level clustering and are reported in vertical bars. States
with substantial expansions before 2011 excluded from the analysis (see Table 2). N=1,140.

41

References
Abdelgawad, T., and L. Egbuonu-Davis. "Preferred drug lists and medicaid prescriptions."
Pharmacoeconomics 24 (3), 2006.55-63.
Adelmann, P. K. "Mental and substance use disorders among medicaid recipients: Prevalence
estimates from two national surveys." Administration and Policy in Mental Health and
Mental Health Services Research 31 (2), 2003.111-129.
American Psychiatric Association. American psychiatric association practice guidelines for the
treatment of psychiatric disorders: Compendium 2006: American Psychiatric
Publications. 2006.
â€”â€”â€”. What is mental illness? 2015.
â€”â€”â€”. American psychiatric association practice guidelines. 2017.
Angrist, J. D., and J. Pischke. Mostly harmless econometrics: An empiricist's companion.
Princeton, NJ: Princeton University Press. 2009.
Autor, D. H. "Outsourcing at will: The contribution of unjust dismissal doctrine to the growth of
employment outsourcing." Journal of Labor Economics 21 (1), 2003.1-42.
Baicker, K., H. L. Allen, B. J. Wright, and A. N. Finkelstein. "The effect of medicaid on
medication use among poor adults: Evidence from oregon." Health Affairs 36 (12),
2017.2110-2114.
Biener, A. I., S. H. Zuvekas, and S. C. Hill. "Impact of recent medicaid expansions on officeâ€
based primary care and specialty care among the newly eligible." Health Services
Research, 2017.
Bishop, T. F., M. J. Press, S. Keyhani, and H. Pincus. "Acceptance of insurance by psychiatrists
and the implications for access to mental health care." JAMA Psychiatry 71 (2),
2014.176-181.
Bradford, W. D., and W. D. Lastrapes. "A prescription for unemployment? Recessions and the
demand for mental health drugs." Health Economics, 2013.
Center for Behavioral Health Statistics and Quality. 2015 national survey on drug use and health:
Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services
Administration. 2016.
Cohen, R., M. Martinez, and B. Ward. Health insurance coverage: Early release of estimates
from the national health interview survey, 2009: National Center for Health Statistics.
2010.
Cook, B. L., N.-H. Trinh, Z. Li, S. S.-Y. Hou, and A. M. Progovac. "Trends in racial-ethnic
disparities in access to mental health care, 2004â€“2012." Psychiatric Services 68 (1),
2016.9-16.
Courtemanche, C., J. Marton, B. Ukert, A. Yelowitz, and D. Zapata. Early effects of the
affordable care act on healthcare access, risky health behaviors, and self-assessed health.
In National Bureau of Economic Research Working Paper Series. Cambridge, MA:
National Bureau of Economic Research. 2017.
â€”â€”â€”. "Early impacts of the affordable care act on health insurance coverage in medicaid
expansion and non-expansion states." Journal of Policy Analysis and Management 36 (1),
2017.178-210.
Cutler, D. M., and J. Gruber. "Does public insurance crowd out private insurance?" Quarterly
Journal of Economics 111 (2), 1996.391-430.

42

Czajka, J. L., and R. Rosso. Redesign of the income questions in the current population survey
annual social and economic supplement: Further analysis of the 2014 split-sample test:
Mathematica Policy Research. 2015.
Decker, S. L. "In 2011 nearly one-third of physicians said they would not accept new medicaid
patients, but rising fees may help." Health Affairs 31 (8), 2012.1673-1679.
Flood, S., M. King, S. Ruggles, and J. R. Warren. Integrated public use microdata series, current
population survey. Minneapolis, MN. 2017.
Frank, R. G., and T. G. McGuire. Economics and mental health. In Handbook of health
economics, edited by A. J. Culyer and J. P. Newhouse Elsevier. 2000.
Frean, M., J. Gruber, and B. D. Sommers. "Premium subsidies, the mandate, and medicaid
expansion: Coverage effects of the affordable care act." Journal of Health Economics 53,
2017.72-86.
Fredriksen, M., A. HalmÃ¸y, S. V. Faraone, and J. Haavik. "Long-term efficacy and safety of
treatment with stimulants and atomoxetine in adult adhd: A review of controlled and
naturalistic studies." European Neuropsychopharmacology 23 (6), 2013.508-527.
Garfield, R. L., J. R. Lave, and J. M. Donohue. "Health reform and the scope of benefits for
mental health and substance use disorder services." Psychiatric Services 61 (11),
2010.1081-1086.
Garfield, R. L., S. H. Zuvekas, J. R. Lave, and J. M. Donohue. "The impact of national health
care reform on adults with severe mental disorders." American Journal of Psychiatry 168
(5), 2011.486-494.
Gaynes, B. N., D. Warden, M. H. Trivedi, S. R. Wisniewski, M. Fava, and A. J. Rush. "What did
star* d teach us? Results from a large-scale, practical, clinical trial for patients with
depression." Psychiatric Services 60 (11), 2009.1439-1445.
Ghosh, A., K. Simon, and B. D. Sommers. The effect of state medicaid expansions on
prescription drug use: Evidence from the affordable care act. In National Bureau of
Economic Research Working Paper Series. Cambridge, MA: National Bureau of
Economic Research. 2017.
Golberstein, E., and G. Gonzales. "The effects of medicaid eligibility on mental health services
and out-of-pocket spending for mental health services." Health Services Research 50 (6),
2015.1734-1750.
Goodman, L. "The effect of the affordable care act medicaid expansion on migration." Journal of
Policy Analysis and Management 36 (1), 2017.211-238.
Grossman, M. "On the concept of health capital and the demand for health." Journal of Political
Economy 80 (2), 1972.223-255.
Hamersma, S., and M. Kim. "Participation and crowd out: Assessing the effects of parental
medicaid expansions." Journal of Health Economics 32 (1), 2013.160-171.
Horn, B. P., J. C. Maclean, and M. R. Strain. "Do minimum wage increases influence worker
health?" Economic Inquiry 55 (4), 2017.1986-2007.
Hu, L., R. Kaestner, B. Mazumder, S. Miller, and A. Wong. The effect of the patient protection
and affordable care act medicaid expansions on financial well-being. In Nationa Bureau
of Economic Research. Cambridge, MA: National Bureau of Economic Research. 2016.
Hurley, R. E., and S. A. Somers. "Medicaid and managed care: A lasting relationship?" Health
Affairs 22 (1), 2003.77-88.
Insel, T. R. "Assessing the economic costs of serious mental illness." American Journal of
Psychiatry 165 (6), 2008.663-5.
43

â€”â€”â€”. Mental health awareness month: By the numbers: National Instite of Mental Health.
2015.
Kaestner, R., B. Garrett, J. Chen, A. Gangopadhyaya, and C. Fleming. "Effects of aca medicaid
expansions on health insurance coverage and labor supply." Journal of Policy Analysis
and Management 36 (3), 2017.608-642.
Kaiser Commission on Medicaid and the Uninsured. Implementing coverage and payment
initiatives: Results from a 50-state medicaid budget survey for state fiscal years 2016 and
2017: Kaiser Commisson on Medicaid and the Uninsured. 2016.
â€”â€”â€”. Medicaid and chip eligibility, enrollment, renewal, and cost-sharing policies as of
january 2016: Findings from a 50-state survey. Washington, DC: Kaiser Family
Foundation. 2016.
Kaiser Family Foundation. Medicaidâ€™s role in behavioral health. 2017.
â€”â€”â€”. Total monthly medicaid and chip enrollment: Kaiser Family Foundation. 2018.
Koma, J. W., J. M. Donohue, C. L. Barry, H. A. Huskamp, and M. Jarlenski. "Medicaid coverage
expansions and cigarette smoking cessation among low-income adults." Medical care 55
(12), 2017.1023-1029.
Lehmann, A., P. Aslani, R. Ahmed, J. Celio, A. Gauchet, P. Bedouch, O. Bugnon, B. Allenet,
and M. P. Schneider. "Assessing medication adherence: Options to consider."
International Journal of Clinical Pharmacy 36 (1), 2014.55-69.
Levinson, D. Higher rebates for brand-name drugs result in lower costs for medicaid compared
to medicare part d. Washington, DC: Department of Health and Human Services Office
of the Inspector General. 2011.
Lieberman, J. A. "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia:
Efficacy, safety and cost outcomes of catie and other trials." The Journal of Clinical
Psychiatry 68 (2), 2007.e04-e04.
Ling, W., C. Charuvastra, J. F. Collins, S. Batki, L. S. Brown, P. Kintaudi, D. R. Wesson, L.
Mcnicholas, D. J. Tusel, and U. Malkerneker. "Buprenorphine maintenance treatment of
opiate dependence: A multicenter, randomized clinical trial." Addiction 93 (4), 1998.475486.
Lovenheim, M. F. "The effect of teachersâ€™ unions on education production: Evidence from union
election certifications in three midwestern states." Journal of Labor Economics 27 (4),
2009.525-587.
Maclean, J. C., M. F. Pesko, and S. C. Hill. The effect of insurance expansions on smoking
cessation medication use: Evidence from recent medicaid expansions. In National Bureau
of Economic Research Working Paper Series. Cambridge, MA: National Bureau of
Economic Research. 2017.
Maclean, J. C., and B. Saloner. The effect of public insurance expansions on substance use
disorder treatment: Evidence from the affordable care act. In National Bureau of
Economic Research Working Paper Series. Cambridge, MA: National Bureau of
Economic Research 2017.
Manning, W. G., and J. Mullahy. "Estimating log models: To transform or not to transform?"
Journal of Health Economics 20 (4), 2001.461-494.
Mark, T. L., W. Olesiuk, M. M. Ali, L. J. Sherman, R. Mutter, and J. L. Teich. "Differential
reimbursement of psychiatric services by psychiatrists and other medical providers."
Psychiatric Services Forthcoming, 2017.appips201700271.

44

Miller, S., and L. R. Wherry. "Health and access to care during the first 2 years of the aca
medicaid expansions." New England Journal of Medicine 376 (10), 2017.947-956.
Moffitt, R. "Incentive effects of the us welfare system: A review." Journal of Economic
Literature 30 (1), 1992.1-61.
Morrill, M. I. "Issues in the diagnosis and treatment of adult adhd by primary care physicians."
Primary Psychiatry 16 (5), 2009.57-63.
Olfson, M. "The rise of primary care physicians in the provision of us mental health care."
Journal of Health Politics, Policy and Law 41 (4), 2016.559-583.
Paradise, J. Data note: Medicaid managed care growth and implications of the medicaid
expansion, edited by K. F. Foundation: Kaiser Family Foundation. 2017.
Richards, M. R., J. Marti, J. C. Maclean, J. Fletcher, and D. Kenkel. "Tobacco control, medicaid
coverage, and the demand for smoking cessation drugs." American Journal of Health
Economics 3 (4), 2017.528-549.
Ridley, D. B., and K. J. Axelsen. "Impact of medicaid preferred drug lists on therapeutic
adherence." Pharmacoeconomics 24 (3), 2006.65-78.
Rosenbaum, S., D. Mehta, M. Dorley, C. Hurt, S. Rothenberg, N. Lopez, and S. Ely. Medicaid
benefit designs for newly eligible adults: State approaches. In Commonwealth Fund Issue
Brief: Commonwealth Fund 2015.
Roth, J. Ndc data -- national drug code data. 2017.
Ruggles, S., K. Genadek, R. Goeken, J. Grover, and M. Sobek. Integrated public use microdata
series: Version 6.0 [dataset]. Minneapolis, MN. 2017.
Simon, K., A. Soni, and J. Cawley. "The impact of health insurance on preventive care and
health behaviors: Evidence from the first two years of the aca medicaid expansions."
Journal of Policy Analysis and Management 36 (2), 2017.390-417.
Solon, G., S. J. Haider, and J. M. Wooldridge. "What are we weighting for?" Journal of Human
Resources 50 (2), 2015.301-316.
Sommers, B. D., R. J. Blendon, E. Orav, and A. M. Epstein. "Changes in utilization and health
among low-income adults after medicaid expansion or expanded private insurance."
JAMA Internal Medicine 176 (10), 2016.1501-1509.
Sommers, B. D., and D. C. Grabowski. "What is medicaid? More than meets the eye." JAMA 318
(8), 2017.695-696.
Sommers, B. D., M. Z. Gunja, K. Finegold, and T. Musco. "Changes in self-reported insurance
coverage, access to care, and health under the affordable care act." JAMA 314 (4),
2015.366-74.
Sommers, B. D., B. Maylone, R. J. Blendon, E. J. Orav, and A. M. Epstein. "Three-year impacts
of the affordable care act: Improved medical care and health among low-income adults."
Health Affairs, 2017.
Soumerai, S. B., J. Avorn, D. Ross-Degnan, and S. Gortmaker. "Payment restrictions for
prescription drugs under medicaid." New England Journal of Medicine 317 (9),
1987.550-556.
Soumerai, S. B., D. Ross-Degnan, J. Avorn, T. J. McLaughlin, and I. Choodnovskiy. "Effects of
medicaid drug-payment limits on admission to hospitals and nursing homes." New
England Journal of Medicine 325 (15), 1991.1072-1077.
Stein, D. J., J. C. Ipser, S. Seedat, C. Sager, and T. Amos. "Pharmacotherapy for post traumatic
stress disorder (ptsd)." The Cochrane Library, 2006.

45

Substance Abuse and Mental Health Services Administration. Adults with mental illness or
substance use disorder account for 40 percent of all cigarettes smoked. In The NSDUH
report. Rockville, MD: Substance Abuse and Mental Health Services Administration.
2013.
Thomas, K. C., A. R. Ellis, T. R. Konrad, C. E. Holzer, and J. P. Morrissey. "County-level
estimates of mental health professional shortage in the united states." Psychiatric
Services 60 (10), 2009.1323-1328.
U.S. Department of Health and Human Services. Statesâ€™ collection of rebates for drugs paid
through medicaid managed care organizations. Washington, DC: U.S. Department of
Health and Human Services, Office of Inspector General. 2012.
Wen, H., B. G. Druss, and J. R. Cummings. "Effect of medicaid expansions on health insurance
coverage and access to care among low-income adults with behavioral health conditions."
Health Services Research 50 (6), 2015.1787-1809.
Wen, H., J. M. Hockenberry, T. F. Borders, and B. G. Druss. "Impact of medicaid expansion on
medicaid-covered utilization of buprenorphine for opioid use disorder treatment."
Medical Care 55 (4), 2017.336-341.
Wherry, L. R., and S. Miller. "Early coverage, access, utilization, and health effects associated
with the affordable care act medicaid expansions: A quasi-experimental study." Annals of
Internal Medicine 164 (12), 2016.795-803.
Winkelman, T. N. A., and V. W. Chang. "Medicaid expansion, mental health, and access to care
among childless adults with and without chronic conditions." Journal of General Internal
Medicine, 2017.
Wolfers, J. "Did unilateral divorce laws raise divorce rates? A reconciliation and new results."
American Economic Review 96 (5), 2006.1802-1820.
World Health Organization. Mental disorders fact sheet: World Health Organization. 2017.
Wright, B. M., E. H. Eiland, and R. Lorenz. "Augmentation with atypical antipsychotics for
depression: A review of evidenceâ€based support from the medical literature."
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (3),
2013.344-359.
Zammitti, E., R. Cohen, and M. Martinez. Health insurance coverage: Early release of estimates
from the national health interview survey, januaryâ€“june 2017. In National Health
Interview Survey Early Release Program. Atlanta, GA: National Center for Health
Statistics. 2017.

46

